TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $29.83.

TGTX has been the topic of several recent research reports. HC Wainwright boosted their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, LADENBURG THALM/SH SH increased their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $18.31 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. The stock has a fifty day moving average price of $16.62 and a 200 day moving average price of $16.08. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $26.95. The company has a market cap of $2.83 billion, a PE ratio of 79.61 and a beta of 2.23.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. TG Therapeutics’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. Sell-side analysts forecast that TG Therapeutics will post -0.01 EPS for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of TG Therapeutics by 2.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,112,682 shares of the biopharmaceutical company’s stock valued at $9,302,000 after buying an additional 31,872 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of TG Therapeutics by 131.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the last quarter. Kestra Advisory Services LLC boosted its stake in shares of TG Therapeutics by 8.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 1,240 shares during the last quarter. Trexquant Investment LP boosted its stake in shares of TG Therapeutics by 170.3% during the 3rd quarter. Trexquant Investment LP now owns 390,507 shares of the biopharmaceutical company’s stock valued at $3,265,000 after buying an additional 246,022 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter valued at approximately $104,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.